Intas Pharma

EMA accepts Intas Pharma’s MAA for DMB-3115

Read more

The animal-human health connect

Read more

Intas and Axantia sign licence and supply agreement for Ranibizumab biosimilar in Middle East

Read more

Intas enters into agreement with Meiji and Dong-A ST to commercialise DMB-3115

Read more

Intas gets DCGI nod for clinical trials of hyperimmune globulin for COVID-19 treatment  

Read more

Naari completes acquisition of ANDAs from Intas Pharmaceuticals

Read more